Ipamorelin
Selective GH Secretagogue
Ipamorelin is the most selective growth hormone releasing peptide (GHRP) studied to date. While earlier GHRPs like GHRP-2 and GHRP-6 trigger a broad hormonal cascade including cortisol and prolactin spikes, ipamorelin releases GH with minimal off-target hormone activity — a meaningful distinction in research design.
At a Glance
Ipamorelin's selectivity comes from its targeted action at the ghrelin receptor (GHSR-1a) without meaningfully activating cortisol or prolactin pathways. This makes it a cleaner tool for isolating the effects of GH stimulation in preclinical models.
It is frequently combined with CJC-1295 (a GHRH analogue) to produce a synergistic GH pulse that more closely mimics the natural pituitary release pattern — a combination that has become one of the most studied in GH secretagogue research.
Its combination with CJC-1295 no-DAC (Mod GRF 1-29) represents a research-optimized approach to mimicking physiological GH pulses, and is among the most cited secretagogue pairings in the literature.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
GHSR-1a Agonism
Selectively binds the ghrelin receptor to stimulate pituitary GH release without meaningful activation of cortisol or prolactin secretion pathways.
GH Pulse Amplification
Amplifies the natural GH pulse amplitude while preserving normal pulsatility patterns — cleaner than continuous GH administration models.
IGF-1 Upregulation
GH release drives hepatic IGF-1 production, supporting downstream anabolic and tissue repair signaling throughout the body.
Sleep Architecture
Preliminary research suggests enhanced slow-wave sleep quality, consistent with the role of GH secretion in sleep physiology.
- Body composition research — fat mass reduction and lean mass preservation in aging models
- GH pulse studies — selective secretagogue with minimal hormonal noise vs GHRP-2/6
- Bone mineral density models — IGF-1-mediated skeletal effects in rodent studies
- Wound healing and tissue repair — GH/IGF-1 pathway contributions to regeneration
- Sleep quality research — correlation with slow-wave GH release timing
- Anti-aging models — GH axis decline and restoration research
- Combination protocols with CJC-1295 for synergistic GH axis stimulation
Ipamorelin, GHRP-2, and GHRP-6 each offer different selectivity profiles — the right choice depends on whether a study needs clean GH isolation or is investigating the full ghrelin-receptor cascade.
| Aspect | Ipamorelin | GHRP-2 | GHRP-6 |
|---|---|---|---|
| Cortisol Release | Minimal | Moderate increase | Moderate increase |
| Prolactin Release | Minimal | Moderate increase | Moderate increase |
| Appetite Stimulation | None | Mild | Strong (significant) |
| GH Pulse Quality | Clean & selective | Broad hormonal | Broad hormonal |
| Research Preference | High selectivity studies | Potency studies | Appetite/GH combo |
Highly selective — minimal cortisol and prolactin release compared to other GHRPs
Well-tolerated in preclinical models with favorable safety profile at studied doses
Stable lyophilized form with long shelf life under proper storage conditions
Human clinical data limited — not an approved therapeutic; long-term human safety not established
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026